Research programme: hepatitis B therapeutics - Arcturus/Janssen Pharmaceuticals

Drug Profile

Research programme: hepatitis B therapeutics - Arcturus/Janssen Pharmaceuticals

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcturus Therapeutics
  • Developer Arcturus Therapeutics; Janssen Pharmaceuticals
  • Class MicroRNAs; RNA; Small interfering RNA
  • Mechanism of Action RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 19 Oct 2017 Arcturus Therapeutics has patents pending for LUNAR lipid-mediated delivery and UNA technology including UNA oligomers in USA, Europe, Japan, China and other countries
  • 11 Nov 2016 Preclinical trials in Hepatitis B in USA (Parenteral)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Hepatitis B presented at the Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top